Biotech Values

[swampboots]

DEW: More the point, uh correct me if I am wrong but previously improvement was discussed (ie. Squalamine, Visudyne) in terms of recognition of more letters (increased visual acuity) not ""less"" reduced recognition of letters (reduced visual acuity), in comparison to placebo group.

"Secondary efficacy analyses were statistically significant and
supported the primary analysis. Treated patients demonstrated
better VA outcomes in terms of mean change from baseline and
reduced severe vision loss (greater than 30 letters)."